Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2021 Jul 21;11:14864. doi: 10.1038/s41598-021-94168-7

Influence of the type of pathogen on the clinical course of infectious complications related to cardiac implantable electronic devices

Anna Polewczyk 1,2,, Wojciech Jacheć 3, Luca Segreti 4, Maria Grazia Bongiorni 4, Andrzej Kutarski 5
PMCID: PMC8295258  PMID: 34290303

Abstract

The specific role of the various pathogens causing cardiac implantable electronic devices-(CIEDs)-related infections requires further understanding. The data of 1241 patients undergoing transvenous lead extraction because of lead-related infective endocarditis (LRIE-773 patients) and pocket infection (PI-468 patients) in two high-volume centers were analyzed. Clinical course and long-term prognosis according to the pathogen were assessed. Blood and generator pocket cultures were most often positive for methicillin-sensitive Staphylococcus aureus (MSSA: 22.19% and 18.13% respectively), methicillin-sensitive Staphylococcus epidermidis (MSSE: 17.39% and 15.63%) and other staphylococci (11.59% and 6.46%). The worst long-term prognosis both in LRIE and PI subgroup was in patients with infection caused by Gram-positive microorganisms, other than staphylococci. The most common pathogens causing CIED infection are MSSA and MSSE, however, the role of other Gram-positive bacteria and Gram-negative organisms is also important. Comparable, high mortality in patients with LRIE and PI requires further studies.

Subject terms: Microbiology, Cardiology

Introduction

Cardiac implantable electronic device (CIED) infection is one of the most dangerous complications in patients with pacemakers (PM), implantable cardiac defibrillators (ICD) and cardiac resynchronization therapy (CRT) devices. The rate of infections in patients with PM/ICD/CRT devices ranges between 0.5 and 2.2% that is approximately 10% of all infective endocarditis cases1,2. Several studies suggest that rate of infectious complications have been increasing over the last two decades and the rate of increase was disproportionate to number of implantations. Patients with PMs and ICDs showed a 2.5-fold and 1.9-fold increase in CIED infection, when comparing 1988–1994 and 1995–20013. The incidence of isolated pocket infection (PI) is estimated to be 1.9/1000 device-years, whereas the incidence of pocket infection with bloodstream infection is 1.14 per 1000 device-years4. The most common pathogens isolated from blood and CIED pocket are staphylococci especially coagulase-negative staphylococci (CoNS) with predominantly Staphylococcus epidermidis (S. epidermidis) and Staphylococcus aureus (S. aureus), less frequently other than staphylococci Gram-positive bacteria (the most common: streptococci, corynobacteriacae and micrococci), Gram-negative pathogens and fungi. Most available reports514 evaluate differences between CoNS and infections caused by S. aureus. This paper investigates the clinical and procedural factors that may influence a particular pathogen in blood and generator pocket, and analyses the impact of pathogen type on the clinical course and survival in patients undergoing transvenous lead extraction (TLE) because of infectious complications.

Methods

Study population and design

We retrospectively analysed data from 3810 patients undergoing TLE in two high-volume centres (Poland and Italy) between 2006 and 2017 for infectious (1758; 46.1%) and noninfectious (2052; 53.9%) indications. Because of incomplete blood and pocket culture results, we excluded 517 infectious patients from further analysis. We assessed clinical data from 1241 patients with infectious indications (773 with lead-related infective endocarditis-LRIE and 468 with isolated pocket infection-PI). The following clinical factors were taken into account: left ventricular ejection fraction (LVEF), NYHA class, prior sternotomy, presence of valvular implants, hypertension, diabetes, history of chronic kidney disease (CKD), permanent atrial fibrillation, and permanent anticoagulation or permanent antiplatelet therapy. The following TLE-related factors were analysed: device type, dwell time of the oldest lead, number of CIED-related procedures before TLE, presence of intracardiac lead abrasion, presence and size of vegetations and number of leads including the abandoned ones. We also compared LRIE and PI subgroups regarding the course and efficacy of TLE: procedure duration, technical difficulty, complete procedural and clinical success, and major and minor complications. Based on the microbiological culture results from removed leads and device pocket we compared clinical and procedural data in patients with infectious complications caused by S. aureus (methicillin-sensitive (MSSA) and methicillin-resistant (MRSA), S. epidermidis (methicillin-sensitive (MSSE) and methicillin-resistant (MRSE), other coagulase-negative staphylococci (methicillin-sensitive (MSSO) and methicillin-resistant (MRSO), other Gram-positive cocci, Gram-negative bacilli, Candida and Aspergillus (fungi), and in patients with negative blood and pocket cultures.

Using survival data obtained from the National Health Service Registry in Italy and from the National Health Fund Registry in Poland, we analysed risk factors for mortality in LRIE and PI subgroups, with particular consideration of pathogen and its impact on long-term prognosis. We constructed survival curves using the Kaplan–Meier method in a group of 3369 patients (infectious and noninfectious cases with complete follow-up).

All patients provided written informed consent prior to study enrollment. The study protocol was approved by the Bioethics Committee at the University in Lublin—ref. number 288/2018/KB/VII and complied with the Declaration of Helsinki.

Definitions

Lead-related infective endocarditis was diagnosed using modified Duke criteria according to the 2015 ESC guidelines for the management of infective endocarditis15 and the European Heart Rhythm Association international consensus document16. The diagnosis of lead-related infective endocarditis was definite in the presence of two major criteria or one major criterion and three minor criteria. According to the current guidelines16, cultures from extracted leads were considered as a minor criterion in the diagnosis of LRIE. Possible LRIE was diagnosed in patients with one major and one minor criterion or 3 minor criteria. Possible LRIE was also included in the current analysis.

A pocket infection was defined as local warmth, erythema, swelling, edema, and pain in or discharge from the device pocket or an erosion or impending erosion of the device without lead-related infective endocarditis15.

Intracardiac lead abrasion was defined as outer insulation macroscopic damage, in the intracardiac portion of the lead, usually in the first 15–20 cm from the tip, with visible discolouration, frequently with conductor externalisation, and not infrequently with purulent discharge17.

Transvenous lead extraction was defined according to HRS and EHRA statements1820 as a procedure involving the removal of a lead implanted for over one year or when more than just a standard stylet was required to remove the lead, or the non-implant vein approach had to be utilised. Complete procedural success of TLE was defined as removal of all targeted leads and material, with the absence of any permanently disabling complication or procedure-related death. Clinical success was achieved in patients with retention of a small part of the lead that did not negatively affect the outcome goals of the procedure1820.

Major and minor complications were defined according to the 2018 EHRA Expert Consensus Statement on Lead Extraction20. They defined major complications as any of the outcomes related to the procedure, which was life-threatening or resulted in death or any unexpected event that caused persistent or significant disability. Minor complications were defined as any undesired event related to the procedure that required medical intervention or minor procedural intervention to remedy, and did not limit persistently or significantly the patient’s function, threaten life or cause death.

Microbiology

In all patients with infectious complications, at least three aerobic and anaerobic blood cultures were performed before TLE. In order to exclude contamination, the criterion of a minimum of two positive cultures was used in the case of the physiological flora. In patients with the symptoms of local infection, a swab specimen was obtained from the generator pocket during TLE. The material drawn from the pocket was spread directly on the culture plate. In patients with suspected generalised infection, without PI symptoms, cultures from extracted leads were also done. A segment of the lead was rolled onto the solid media (Chocolate agar, McConkey agar, mannitol salt agar, and Sabouroud agar).

Transvenous lead extraction

The TLE procedures in the two high-volume Polish and Italian centres were performed with the mechanical system based on cutting-rotation forces of telescopic polypropylene Byrd dilators (Cook Medical, Bloomington, IN, USA) of various lengths and sizes.

Leads were usually extracted by simple traction or mechanical dilatation using polypropylene sheaths through the implant vein. Sometimes, in more complicated cases, other venous approaches (jugular and/or femoral) or Evolution Mechanical Dilator Sheath (Cook Medical, Bloomington, IN, USA) or TightRail (Spectranetics Corporation, Colorado Springs) systems were used. We have never used laser energy or radiofrequency wave technology.

Statistical methods

Normality was checked using the Shapiro–Wilk test, which showed that most continuous variables followed normal distribution. For uniformity, all continuous variables are presented as mean ± standard deviation and were compared using the Kruskal–Wallis ANOVA and Mann–Whitney U test. Categorical data are presented as absolute numbers and percentage and were compared using the Chi-square test with Yates correction.

A stepwise multivariable Cox regression model was used to evaluate the role of pathogens as risk factors for long-term mortality after TLE and included the following variables: gender, patient age at the time of TLE, NYHA class, LVEF, presence of artificial valve, arterial hypertension, diabetes mellitus, creatinine concentration, haemoglobin concentration, atrial fibrillation, anticoagulant and antiplatelet therapy, TLE of ICD leads (single or dual coil), presence of vegetations (LRIE), radiological success, pathogen type (MSSA, MRSA, MSSE, MRSE, MSSO, MRSO, other Gram-positive, Gram-negative pathogens, and fungi). Analyses were performed for patients with LRIE and pocket infection. In multivariable analysis, the results were presented as hazard ratio (HR) with 95% confidence interval (CI).

The Kaplan–Meier method was used to calculate the probability of event free survival depending on culture results from blood (LRIE) or pocket (PI) and in all subgroups divided according to indications for TLE (noninfectious, PI or LRIE). The log-rank test, including complete and censored data, was used to test for differences between survival curves.

A two-tailed p value < 0.05 was considered statistically significant. Statistical analysis was performed using STATISTICA 13.1 PL (TIBCO, Cracow, Poland).

Results

The study population comprised 1241 patients with infectious complications, including 773 (62.29%) with LRIE, and 468 (37.71%) with isolated PI. The distribution of bacterial isolates from blood cultures in patients with LRIE was: MSSA: 22.19%, MSSE: 17.39%, MSSO: 11.59%, MRSE: 9.74%, Gram-negative: 9.12%, MRSA: 1.73%, MRSO: 2.10%, other Gram-positive: 2.34%, fungi 0.74%. Blood cultures were negative in 23.06% of cases (Fig. 1). Gram-negative were concurrent with other bacteria in 20 cases, while staphylococci were concurrent with other bacteria in 14 cases, but there was no concurrent infection of S. aureus or S. epidermidis with other pathogens (Fig. 1, Table S1).

Figure 1.

Figure 1

LRIE subgroup—list of pathogens.

In PI patients pocket cultures were positive for MSSA in 18.13%, MSSE in 15.63%, MSSO in 6.46%, Gram-negative in 5.00%, MRSE in 4.79%, MRSA in 2.08%, MRSO in 0.63%, other Gram-positive in 0.41% and fungi in 0.41%. The rate of negative cultures was 46.46% (Fig. 2). Staphylococci were concurrent with other bacteria in 5 cases, whereas Gram-negative bacteria were isolated with other pathogens in 7 patients (Fig. 2, Table S1).

Figure 2.

Figure 2

PI subgroup—list of pathogens.

In patients with suspected LRIE, besides blood cultures, 657 lead cultures from the extracted leads were analysed. Lead cultures were positive in 504 patients, including 24 patients with negative blood cultures. In these 24 patients with negative blood cultures, we identified 27 pathogens: S. epidermidis (51.85%) and other staphylococci (44.44%) were predominant.

Comparison of clinical and procedural factors in patients with LRIE and PI

Patients in LRIE subgroup were more likely to have higher NYHA class (1.699 ± 0.774 vs. 1.574 ± 0.707; p = 0.008), diabetes mellitus (23.88% vs. 18.92%; p = 0.039) and renal failure (6.77% vs. 3.15%; p = 0.039), but permanent atrial fibrillation (21.76% vs. 26.82%; p = 0.042) was less common than in PI patients. The remaining clinical parameters were similar in both subgroups (Table 1).

Table 1.

Demographic and clinical data of patients admitted for lead extraction due to infection.

All group (patients with CIED related infections)
N = 1241
LRIE
N = 773
(62.29)
PI
N = 468
(37.71)
p
“U” Mann–Whitney/Chi2
Demographics

Male

n (%)

908

(73.00)

n = 1241

559

(72.32)

n = 773

349

(74.15)

n = 468

p = 0.389

Female

n (%)

333

(26.99)

n = 1241

214

(27.68)

n = 773

119

(25.85)

n = 468

p = 0.389

Mean age (first implantation)

mean ± sd

60.811 ± 14.966

n = 1241

60.435 ± 14.693

n = 773

61.365 ± 15.278

n = 468

0.107

Mean age (TLE), mean, SD

Mean ± SD

67.947 ± 13.662

n = 1241

67.802 ± 13.378

n = 773

68.130 ± 14.053

n = 468

0.380

BMI [kg/m2]

Mean ± SD

27.105 ± 4.028

n = 1199

27.205 ± 4.252

n = 710

26.917 ± 3.583

n = 389

0.250
Clinical data

LVEF [%]

Mean ± SD

48.114 ± 14.363

n = 1190

48.107 ± 14.226

n = 750

48.050 ± 14.249

n = 440

p = 0.806

NYHA class

Mean ± SD

1.740 ± 3.143

n = 1235

1.699 ± 0.774

n = 770

1.574 ± 0.707

n = 465

0.008

Presence of valvular implants

n (%)

75

(6.04)

n = 1241

46

(5.95)

n = 773

29

(6.20)

n = 468

p = 0.857

Prior sternotomy

n (%)

194

(15.84)

n = 1225

122

(15.80)

n = 759

72

(16.14)

n = 466

p = 0.881

Arterial hypertension

n (%)

774

(62.37)

1241

486

(62.87)

773

288

(61.54)

468

p = 0.682

Diabetes

n (%)

270

(22.00)

n = 1227

182

(23.88)

n = 762

88

(18.92)

n = 465

p = 0.039

History of CKD or eGFR < 60 ml/min/1.73 m2

n (%)

62

(5.45)

n = 1137

49

(6.77)

n = 724

13

(3.15)

n = 413

p = 0.014

Creatinine concentrations [mg/dl]

Mean ± SD

1.264

 ± 0.831

n = 1137

1.308

 ± 0.865

n = 724

1.186

 ± 0.762

n = 413

p = 0.021

Permanent atrial fibrillation

n (%)

291

(23.68)

n = 1229

166

(21.76)

n = 763

125

(26.82)

n = 466

p = 0.042

Permanent anticoagulation

n (%)

391

(32.58)

n = 1200

248

(32.98)

n = 752

144

(32.14)

n = 448

p = 0.810

Permanent antiplatelet therapy

n (%)

476

(39.67)

n = 1200

304

(40.43)

n = 752

172

(38.39)

n = 448

p = 0.447
Preoperative pacing system information

Device without ICD lead

n (%)

794

(63.98)

n = 1241

499

(64.55)

n = 773

295

(63.03)

n = 468

p = 0.550

Device with ICD lead

n (%)

447

(36.02)

1241

274

(35.45)

773

173

(36.97)

468

p = 0.550
Dwelling time for oldest lead [months], Mean ± SD

86.525 ± 69.373

n = 1241

89.187 ± 69.686

n = 773

82.011 ± 68.717

n = 468

p = 0.047
Number of CIED-related operative procedures before TLE (upgrading, pocket revision) Mean ± SD

0.838 ± 1.197

n = 1241

0.816 ± 1.266

n = 773

0.868 ± 1.065

n = 468

p = 0.016
Number of all operative procedures before TLE (implantations, reimplantation, upgrading, pocket revision) Mean ± SD

2.413 ± 1.561

n = 1241

2.425 ± 1.654

n = 773

2.385 ± 1.389

n = 468

p = 0.306

Presence of intracardiac lead abrasion

n (%)

213

(26.93)

n = 791

163

(29.37)

n = 555

50

(21.19)

(n = 236)

p = 0.017

Number of leads in system

Mean ± SD

1.956 ± 0.673

n = 1241

1.948 ± 0.670

n = 773

1.970 ± 0.679

n = 468

p = 0.559

Number of patients with abandoned leads

n (%)

246

(19.82)

N = 1241

162

(20.95)

N = 773

84

(17.95)

N = 468

p = 0.224
Mean number of abandoned leads in patients Mean ± SD

0.255 ± 0.627

n = 1241

0.267 ± 0.613

n = 773

0.235 ± 0.639

n = 468

p = 0.304

Total number of leads in patient

Mean ± SD

2.211 ± 0.859

n = 1241

2.214 ± 0.873

n = 773

2.205 ± 0.820

n = 468

p = 0.889

Vegetations presence

n (%)

522

(42.06)

n = 1241

522

(67.53)

n = 773

0

(0.00)

n = 468

p < 0.001

Presence of large vegetation > 2 cm2

n (%)

146

(11.76)

n = 1241

146

(18.89)

n = 773

0

(0.00)

n = 468

p < 0.001
TLE procedure

Technical problems or complications during TLE

Mean ± SD

0.152 ± 0.359

n = 1241

0.145 ± 0.352

n = 773

0.163 ± 0.370

n = 468

p = 0.401
Number of patients with technical problems or complications during TLE n(%)

188

(15.15)

n = 1241

112

(14.45)

n = 773

76

(16.24)

n = 468

p = 0.401

Procedure duration time [min]

Mean ± SD

105.280 ± 50.684

n = 1241

107.854 ± 50.017

n = 766

100.869 ± 44.346

n = 464

p = 0.077

Radiological success

n (%)

1172

(94.44)

n = 1241

732

(94.70)

n = 773

441

(94.23)

n = 468

p = 0.254

Clinical success

n (%)

1199

(96.62)

n = 1241

749

(96.90)

n = 773

450

(96.15)

n = 468

p = 0.594

Major complications

n (%)

18

(1.45)

n = 1241

14

(1.81)

n = 773

4

(0.85)

n = 468

p = 0.175

Minor complications

n (%)

69

(5.56)

n = 1241

48

(6.21)

n = 773

21

(4.49)

n = 468

p = 0.200

Periprocedural deaths

n (%)

7

(5.46)

n = 1241

6

(0.78)

n = 773

1

(0.21)

n = 468

p = 0.200

Follow-up [days]

Mean ± SD

1589,0

 ± 1041,2

n = 1071

1543,9

 ± 1042,1

n = 696

1672,7

 ± 1035,7

n = 375

p = 0.732

Death during follow-up

n (%)

369

(34.45)

n = 1071)

254

(36.49)

n = 696)

115

(30.67)

n = 375

p = 0.065

AF, atrial fibrillation; CIED, cardiac implantable electronic devices; CKD, chronic kidney disease; eGFR, glomerular filtration rate; ICD, implantable cardioverter defibrillator; LRIE, lead related infective endocarditis, LVEF, left ventricular ejection fraction, PI, pocket infections, SD, standard deviation, TLE, transvenous lead extraction.

About device-related and procedural factors, patients with LRIE had older leads (89.187 ± 69.686 vs. 82.011 ± 68.717 dwelling time, in months; p = 0.047) and more frequent intracardiac lead abrasion (29.37% vs. 21.19%; p = 0.017), whereas patients with PI underwent more CIED-related procedures (upgrading, revision of the pocket) (0.868 ± 1.065 vs. 0.816 ± 1.266; p = 0.016). The remaining factors that might influence the course of TLE did not differ between LRIE and PI subgroups. Course of the extraction procedure, radiological and clinical success rates, technical complications and major and minor complications, and mortality during follow-up did not differ between subgroups (Table 1).

LRIE patients: analysis of clinical and procedural factors according to pathogens isolated from blood

Among patients with LRIE divided according to pathogen type, males were most likely to have staphylococcal infection (especially S. aureus; 82.99%). Patients with infection caused by S. aureus were the oldest at the time of first device implantation (mean age 63.902 ± 13.664 years), whereas patients with S. epidermidis and with other staphylococci in blood cultures were the youngest at implantation (58.973 ± 14.707 and 58.320 ± 15.184 years, respectively). Mean age of all patients with LRIE during TLE was similar, regardless of the pathogen type. Patients with infection caused by S. aureus were most likely to have chronic kidney disease, whereas in patients with S. epidermidis and other staphylococci, CKD was less common. Patients with Gram-negative bacteria in blood cultures were more often on chronic anticoagulation (51.92%) as compared with other subgroups. The remaining clinical parameters were similar for all pathogens (Table S2).

On device-related factors, patients with infection caused by S. aureus had shorter lead dwell times (dwell time of the oldest extracted lead was 75.954 ± 70.027 months) whereas patients with other staphylococci and S. epidermidis had the oldest leads (lead dwell times of 98.711 ± 67.54 and 93.740 ± 65.033 months, respectively).

The highest number of CIED-related procedures before TLE (2.785 ± 1.778) characterised patients with infection caused by S. epidermidis. Patients with Candida/Aspergillus and other staphylococci had the least number of leads in the system (1.333 ± 0.516 and 1.814 ± 0.565, respectively). Rates of complete procedural success, clinical success, major and minor complications were similar in all LRIE subgroups. Vegetations were most common in patients with infections caused by S. aureus (67.01%) (Table S2).

PI patients: analysis of clinical and procedural factors according to pathogens isolated from generator pocket

S. epidermidis (20.94%), S. aureus (20.73%) and other staphylococci (6.62%) were the predominant pathogens in patients with PI, while other Gram-positive bacteria (0.43%) were the least common organisms. S. aureus was most present in males (83.51%), since Gram-negative bacteria were more common in women (64.71%). Patients with other Gram-positive bacteria in pocket cultures were the oldest (80.000 ± 4.243 years), whereas patients with other staphylococci were the youngest (59.323 ± 17.213 years) at the time of device implantation. The subgroups did not differ in patient age during TLE. There were no subgroup differences in left ventricular ejection fraction, but patients with other Gram-positive bacteria in cultures were in the highest NYHA class (3.000 ± 0.000 on average), whereas the lowest NYHA class was observed in patients with other staphylococci (1.355 ± 0.551). Gram-negative bacteria in pocket cultures were more common in patients after sternotomy (41.18% patients). The remaining clinical factors did not differ between subgroups (Table S3).

Among procedural factors, lead dwell times were shorter in patients with local infection because of Gram-negative bacteria (41.412 ± 44.626 months). Patients with other staphylococci had a higher number of implanted leads (2.226 ± 0.735) as compared with S. aureus and S. epidermidis subgroups. Abandoned leads were most common in S. aureus subgroup i.e. in 23.71% of patients. The efficacy of TLE and major and minor complications were similar in all subgroups (Table S3).

Long-term survival after TLE: analysis according to type of infectious complications

During long-term follow-up (median: 4.121 years; IQR 2.041–6.648) there were 254 (36.49%) deaths in LRIE subgroup and 115 (30.67%) deaths in PI patients (p = 0.065) (Table 1). Mortality in patients with LRIE and PI was significantly higher than in patients undergoing TLE for noninfectious indications (p < 0.001) (Fig. 3).

Figure 3.

Figure 3

Kaplan–Meier probability of survival depending on indications for transvenous lead extraction procedure.

Long term survival after TLE in LRIE patients: analysis according to pathogen

At long-term follow-up the highest mortality was observed in patients with other than staphylococci Gram-positive bacteria (62.5% of deaths during mean follow-up of 1503.8 ± 1265.8 days) and with Gram-negative bacteria (mortality of 43.75% during mean follow-up of 1291.2 ± 450.0 days). Fungal infection was associated with high mortality rates (60% of deaths during mean follow-up of 1291.2 ± 450.0 days) during a short follow-up. The lowest mortality rate was observed in patients with negative blood cultures (32.56% during 1368.3 ± 1024.8 days of follow-up) and with S. epidermidis infection (34.33% of deaths during mean follow-up of 1867.4 ± 1044 days) (Table S2, Fig. 4).

Figure 4.

Figure 4

Probability of survival in patients with LRIE depending on pathogen type.

Long term survival after TLE in LRIE patients: Multivariable analysis of mortality risk factors

Factors that increased mortality risk during long-term follow-up were heart failure (higher NYHA class and lower LVEF), permanent atrial fibrillation, renal failure (higher creatinine levels), anaemia and older patient age. Infection due to MSSE was associated with better long-term survival rates (Table 2).

Table 2.

Risk factors for deaths after TLE in LRIE patients.

n = 641 (complete data) HR 95% CI p
Age of patients during TLE (1 year) 1.031 1.019–1.044 < 0.001
NYHA (1 class) 1.500 1.250–1.800 < 0.001
Lower LVEF (1%p) 1.017 1.007–1.027 < 0.001
Permanent atrial fibrillation 1.389 1.050–1.837 0.021
Lower haemoglobin concentration (1 g/dl) 1.075 1.005–1.149 0.035
Creatinine (1 mg %) 1.277 1.134–1.439 < 0.001
Pathogen other than MSSE 1.876 1.256–2.703 < 0.001

Results of multivariable stepwise Cox regression model.

LRIE, lead related infection endocarditis, LVEF, left ventricular ejection fraction, MSSE, methicillin sensitive S. epidermidis; NYHA, New York Heart Association (class), TLE, transvenous lead extraction.

Long term survival after TLE in PI patients: analysis according to pathogen

During follow-up of 407.00 ± 26.87 days, the highest mortality (100%) was observed in patients with Candida albicans (mean follow-up of 602.00 ± 374.767 days) and other than staphylococci Gram-positive bacteria in pocket cultures. Death rates were also high in patients with Gram-negative bacteria in pocket cultures (57.14% of deaths during mean follow-up of 1430.5 ± 1077.1 days). We observed best survival outcomes in patients with other than S. aureus and S. epidermidis organisms in pocket cultures (13.3% mortality during mean follow-up of 2091.1 ± 1221.3 days) (Table S3, Fig. 5).

Figure 5.

Figure 5

Probability of survival in patients with PI depending on pathogen type.

Long-term survival after TLE in PI patients: multivariable analysis of mortality risk factors

At long-term follow-up Candida albicans isolated from pocket cultures, diabetes, heart failure (higher NYHA class and lower LVEF), arterial hypertension, anaemia and older patient age were the risk factors for mortality in patients with PI (Table 3).

Table 3.

Risk factors for deaths after TLE in PI patients.

n = 325 (complete data) HR 95% CI p
Age of patients during TLE (1 year) 1.023 1.003–1.043 0.022
NYHA (1 class) 1.705 1.251–2.324 < 0.001
Lower LVEF (1%p) 1.018 1.003–1.034 0.018
Arterial hypertension 1.671 1.019–2.738 0.042
Diabetes 1.809 1.136–2.879 0.012
Lower haemoglobin concentration (1 g/dl) 1.311 1.166–1.473 < 0.001
Creatinine (1 mg %) 1.144 0.992–1.319 0.065
Candida albicans pocket culture 15.630 3.451–70.798 < 0.001

Results of multivariable stepwise Cox regression model.

LVEF—Left ventricular ejection fraction; NYHA—New York Heart Association (class); PI—pocket infection; TLE—transvenous lead extraction.

Discussion

Infectious complications in patients with CIEDs have specific characteristics related to the foreign body reaction. There are two mechanisms of CIED infection. One mechanism involves contamination at the time of first implantation or other CIED-related procedures before TLE, with subsequent bacterial colonisation and infection spread along the leads to the endocardium. The other mechanism is associated with primary bloodstream infection4,21. Infectious complications in CIED patients can be divided into local pocket infection and a generalised response i.e. lead-related infective endocarditis. Comparative analysis of patients with PI and LRIE in this study, similar to earlier reports2224, showed that patients with generalised infection were most likely to have concomitant diseases (heart failure, diabetes, renal failure, permanent atrial fibrillation), and specific procedural factors: longer lead dwell times and intracardiac lead abrasions. PI, as compared with LRIE, was associated with a higher number of CIED-related procedures before TLE. Detailed microbiological analysis in the study population confirmed that MSSA and MSSE were the most frequent pathogens, causing infectious complications in patients with CIEDs. The incidence of these organisms has been reported to range between 17 and 45% and between 20.5 and 67%, which is comparable to that in the present study514. Our analysis also revealed a relatively frequent (11.59%) incidence of MSSO, with coagulase-negative strains such as S. hominis, S. capitis, S. haemolyticus being predominant. Isolation of CoNS usually represents a challenge for the clinician since it may result from contamination, given the generally low pathogenicity of CoNS except for S. lugdunensis which causes infections with a more severe course, resembling that of S. aureus8. These considerations may explain the different outcome of patients with isolation of other staphylococci in case of PI or LRIE (Figs. 4, 5).

Similar to earlier studies10,14,25 this investigation confirmed the observations on risk factors and course of infections caused by S. aureus and other CoNS. S. aureus infection occurred in patients with shorter lead dwell times, whereas infection caused by S. epidermidis was more common in patients with earlier CIED-related procedures.

Apart from the most typical staphylococcal etiology in CIED infection, in this study Gram-negative bacteria caused infection in 9.12% of LRIE patients and in 5% of PI patients. Similar levels of incidence rates have been reported in recent years26,27. According to earlier studies, Gram-negative bacteria were rarely the primary cause of CIED infection, a milder course and lower long-term mortality characterised which, as compared with typical staphylococcal infection28. However, recent reports have showed that CIED is one of significant risk factors for the development of infective endocarditis because of Gram-negative organisms26. This study showed that Gram-negative bacteria was associated with a high rate of death among patients with LRIE and PI (43.75% and 57.14%, respectively) during 4-year follow-up after TLE. Observations about long-term prognosis in patients with CIED infection due to Gram-negative bacteria are very rare. Recent studies in populations with infective endocarditis including LRIE have shown the 15%-30% mortality rate at one-year follow-up26,29. The worse survival rate of patients with Gram negative infections in the current population may be related to the relatively high coexistence of other bacteria in cultures.

Analysis of long-term survival data from patients undergoing TLE because of CIED infection in our study showed the highest death rates in patients with other than staphylococci Gram positive infections (62.5% in LRIE and 100% in PI subgroup). This pathogenic group has first streptococci, corynobacteriacae and micrococci. The subgroup size in our study was small (16 patients with LRIE and 2 patients with PI), but these results are consistent with other research which found high mortality in patients with less typical CIED infection, caused by streptococci25,30. Detailed microbiological analysis of CIED infections in this study showed also best long-term prognosis for patients with MSSE in blood cultures. These findings match those observed in earlier studies which compared first survival in patients with S. aureus and CoNS14. Most of the studies focused on in-hospital and 12-month mortality showing that S. aureus infection was associated with about 20–25% of deaths at one year and the shortest survival14,30,31. It should be emphasised that there are only single reports assessing mortality over a longer follow-up period. Analysis of survival in 5817 patients with CIED infection showed a 53.8% rate of death in patients after PM implantation during 3-year follow-up vs. 33% in patients without infection (p < 0.001), 47.7% vs. 31.6% (p < 0.001) in patients with ICDs, and 50.8% vs. 36.5% (p < 0.001) in patients with CRT devices. The investigators emphasise that the cause of such high mortality rates is unknown and requires further research32. In contrast, a study in 197 patients with CIED infection showed a 35.4% mortality rate at 5 years (mean follow-up 25 months (12–70) and the rate was like that in the noninfectious control group9. Our study during mean follow-up of 1589.0 ± 1041.2 days showed a 36.49% rate of death in patients with LRIE and 30.67% in patients with PI, which was higher than compared with death rates in patients undergoing TLE for noninfectious reasons. Although direct comparison showed that differences in death rates between PI and LRIE subgroups approached borderline statistical significance (Chi2 p = 0.065), survival curves differed between subgroups (log rank p < 0.001). Most of the available studies show better survival in patients with local infection than in those with generalised infection30,33,34. A recent study has documented similar survival rates in patients with PI and LRIE during over 2-year follow-up (p = 0.791), but the study was carried out in a small group of patients (107 subjects)35. We need further research to explain reasons behind poor long-term survival in PI patients in our study; this result can be attributed to difficulties in evaluating infection spread. This is likely because the present study documented high mortality in the PI and LRIE subgroups with the same cultures: other than Gram-positive and Gram-negative bacteria. Another important issue is the try to explain the reasons for the worse long-term survival in patients after treatment because of CIED infection. Both in LRIE and PI patients the predominant risk factors for mortality were clinical factors: patient age, heart failure, atrial fibrillation, renal failure, anaemia. In PI subgroup it was arterial hypertension, diabetes and local infection with Candida albicans. Several reports have shown a similar relationship between clinical factors and long-term survival after CIED infection9,30,34,36,37, but detailed analysis of risk adjusted for age, gender, race/ethnicity, and the 28 comorbidities from the Elixhauser system in a large population of PM/ICD/CRT-D recipients32 showed that high mortality in patients with CIED infection can persist for at least 1–3 years after the infection and is device-dependent. The worse long-term prognosis in patients after treatment for CIED infection prompts us to continue looking for the causes of low efficacy of the therapy.

Study limitations

This is a retrospective analysis, and we collected the data only in two high-volume centres of TLE. Because of this limitation it is not possible to assess the causes of the high rates of negative blood and pocket cultures, which is probably related to sampling during antibiotic therapy in institutions referring patients for TLE. There is no possibility of evaluating the post-TLE course (as we refer patients to the sending institution)–duration of antibiotic treatment, which may affect long-term survival, is unknown. It is not possible, either, to test the direct causes of death during long-term follow-up.

Conclusions

CIED infection contributes to a poorer clinical course and long-term prognosis in patients undergoing transvenous lead extraction. The most common pathogens causing CIED infection are MSSA and MSSE, however special attention should be given to the adverse effects on the long-term survival in patients with other Gram-positive bacteria and Gram-negative organisms in blood or pocket cultures. Clinical assessment of patients with local infection is important, as the long-term prognosis in this group is comparable to that in LRIE patients.

Supplementary Information

Supplementary Tables. (52KB, docx)

Abbreviations

CIED

Cardiac implantable electronic device

CoNS

Coagulase-negative staphylococci

CKD

Chronic kidney disease

CRT

Cardiac resynchronization therapy

ICD

Implantable cardiac defibrillators

LRIE

Lead related infective endocarditis

LVEF

Left ventricle ejection fraction

MSSA

Methicillin sensitive Staphylococcus aureus

MRSA

Methicillin resistant Staphylococcus aureus

MSSO

Methicillin sensitive other staphylococcus

MRSA

Methicillin resistant other staphylococcus

NYHA

New York Heart Association class

TLE

Transvenous lead extraction

Author contributions

A.P. written manuscript, W.J. statistical study, L.S. material collection, checking paper, M.G.B. material collection, checking paper, A.K. material collection, design of the study.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-021-94168-7.

References

  • 1.Sandoe JA, Barlow G, Chambers JB, Gammage M, Guleri A, Howard P, Olson E, Perry JD, Prendergast BD, Spry MJ, Steeds RP, Tayebjee MH, Watkin R. British guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. J Antimicrob Chemother. 2015;70:325–359. doi: 10.1093/jac/dku383. [DOI] [PubMed] [Google Scholar]
  • 2.Murdoch DR, Corey GR, Hoen B, Miró JM, Fowler VG, Jr, Bayer AS, Karchmer AW, Olaison L, Pappas PA, Moreillon P, Chambers ST, Chu VH, Falcó V, Holland DJ, Jones P, Klein JL, Raymond NJ, Read KM, Tripodi MF, Utili R, Wang A, Woods CW, Cabell CH, International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: The International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med. 2009;169:463–473. doi: 10.1001/archinternmed.2008.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Dai M, Cai C, Vaibhav V, Sohail MR, Hayes DL, Hodge DO, Tian Y, Asirvatham R, Cochuyt JJ, Huang C, Friedman PA, Cha YM. Trends of cardiovascular implantable electronic device infection in 3 decades: A population-based study. JACC Clin Electrophysiol. 2019;5:1071–1080. doi: 10.1016/j.jacep.2019.06.016. [DOI] [PubMed] [Google Scholar]
  • 4.Uslan DZ, Sohail MR, St Sauver JL, Friedman PA, Hayes DL, Stoner SM, Wilson WR, Steckelberg JM, Baddour LM. Permanent pacemaker and implantable cardioverter defibrillator infection: A population-based study. Arch Intern Med. 2007;167:669–675. doi: 10.1001/archinte.167.7.669. [DOI] [PubMed] [Google Scholar]
  • 5.Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, Steckelberg JM, Stoner S, Baddour LM. Management and outcome of permanent pacemaker and implantable cardioverter–defibrillator infections. J Am Coll Cardiol. 2007;49:1851–1859. doi: 10.1016/j.jacc.2007.01.072. [DOI] [PubMed] [Google Scholar]
  • 6.Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL. Infective endocarditis complicating permanent pacemaker and implantable cardioverter–defibrillator infection. Mayo Clin Proc. 2008;83(1):46–53. doi: 10.4065/83.1.46. [DOI] [PubMed] [Google Scholar]
  • 7.Massoure PL, Reuter S, Lafitte S, Laborderie J, Bordachard P, Clementy J, Roudaut R. Pacemaker endocarditis: clinical features and management of 60 consecutive cases. Pacing Clin Electrophysiol. 2007;30(1):12–9. doi: 10.1111/j.1540-8159.2007.00574.x. [DOI] [PubMed] [Google Scholar]
  • 8.Bongiorni MG, Tascini C, Tagliaferri E, Di Cori A, Soldati E, Leonildi A, Zucchelli G, Ciullo I, Menichetti F. Microbiology of cardiac implantable electronic device infections. Europace. 2012;14:1334–1339. doi: 10.1093/europace/eus044. [DOI] [PubMed] [Google Scholar]
  • 9.Deharo JC, Quatre A, Mancini J, Khairy P, Le Dolley Y, Casalta JP, Peyrouse E, Prévôt S, Thuny F, Collart F, Raoult D, Habib G, Franceschi F. Long-term outcomes following infection of cardiac implantable electronic devices: A prospective matched cohort study. Heart. 2012;98:724–733. doi: 10.1136/heartjnl-2012-301627. [DOI] [PubMed] [Google Scholar]
  • 10.Greenspon AJ, Prutkin JM, Sohail MR, Vikram HR, Baddour LM, Danik SB, Peacock J, Falces C, Miro JM, Blank E, Naber C, Carrillo RG, Tseng CH, Uslan DZ. Timing of the most recent device procedure influences the clinical outcome of lead-associated endocarditis results of the MEDIC (Multicenter Electrophysiologic Device Infection Cohort) J Am Coll Cardiol. 2012;14(59):681–687. doi: 10.1016/j.jacc.2011.11.011. [DOI] [PubMed] [Google Scholar]
  • 11.Gandhi T, Crawford T, Riddell J., 4th Cardiovascular implantable electronic device associated infections. Infect Dis Clin N Am. 2012;26:57–76. doi: 10.1016/j.idc.2011.09.001. [DOI] [PubMed] [Google Scholar]
  • 12.Tarakji KG, Chan EJ, Cantillon DJ, Doonan AL, Hu T, Schmitt S, Fraser TG, Kim A, Gordon SM, Wilkoff BL. Cardiac implantable electronic device infections: Presentation, management, and patient outcomes. Heart Rhythm. 2010;7:1043–1047. doi: 10.1016/j.hrthm.2010.05.016. [DOI] [PubMed] [Google Scholar]
  • 13.Viola GM, Awan LL, Ostrosky-Zeichner L, Chan W, Darouiche RO. Infections of cardiac implantable electronic devices a retrospective multicenter observational study. Medicine. 2012;91(3):123–130. doi: 10.1097/MD.0b013e31825592a7. [DOI] [PubMed] [Google Scholar]
  • 14.Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, Wilson WR, Steckelberg JM, Baddour LM, Mayo Cardiovascular Infections Study Group Clinical features and outcomes of cardiovascular implantable electronic device infections due to Staphylococcal species. Am J Cardiol. 2012;110:1143–1149. doi: 10.1016/j.amjcard.2012.05.052. [DOI] [PubMed] [Google Scholar]
  • 15.Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, Dulgheru R, El Khoury G, Erba PA, Iung B, Miro JM, Mulder BJ, Plonska-Gosciniak E, Price S, Roos-Hesselink J, Snygg-Martin U, Thuny F, Tornos Mas P, Vilacosta I, Zamorano JL, ESC Scientific Document Group ESC guidelines for the management of infective endocarditis: the Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Eur Heart J. 2015;36:3075–128. doi: 10.1093/eurheartj/ehv319. [DOI] [PubMed] [Google Scholar]
  • 16.Blomström-Lundqvist C, Traykov V, Erba PA, Burri H, Nielsen JC, Bongiorni MG, Poole J, Boriani G, Costa R, Deharo JC, Epstein LM, Sághy L, Snygg-Martin U, Starck C, Tascini C, Strathmore N. European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2020; 1; 41: 2012–2032 [DOI] [PubMed]
  • 17.Kutarski A, Małecka B, Kołodzinska A, Grabowski M. Mutual abrasion of endocardial leads: Analysis of explanted leads. Pacing Clin Electrophysiol. 2013;36:1503–1501. doi: 10.1111/pace.12216. [DOI] [PubMed] [Google Scholar]
  • 18.Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG, Carrillo RG, Crossley GH 3rd, Epstein LM, Friedman RA, Kennergren CE, Mitkowski P, Schaerf RH, Wazni OM (2009) Heart Rhythm Society; American Heart Association: Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management. Heart Rhythm, 2009; 6: 1085–1104. [DOI] [PubMed]
  • 19.Kusumoto FM, Schoenfeld MH, Wilkoff BL, Berul CI, Birgersdotter-Green UM, Carrillo R, Cha YM, Clancy J, Deharo JC, Ellenbogen KA, Exner D, Hussein AA, Kennergren C, Krahn A, Lee R, Love CJ, Madden RA, Mazzetti HA, Moore JC, Parsonnet J, Patton KK, Rozner MA, Selzman KA, Shoda M, Srivathsan K, Strathmore NF, Swerdlow CD, Tompkins C, Wazni O. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503–e551. doi: 10.1016/j.hrthm.2017.09.001. [DOI] [PubMed] [Google Scholar]
  • 20.Bongiorni MG, Burri H, Deharo JC, Starck C, Kennergren C, Saghy L, Rao A, Tascini C, Lever N, Kutarski A, Fernandez Lozano I, Strathmore N, Costa R, Epstein L, Love C, Blomstrom-Lundqvist C; ESC Scientific Document Group. ESC Scientific Document Group. 2018 EHRA expert consensus statement on lead extraction: Recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: Endorsed by APHRS/HRS/LAHRS. Europace. 2018 1; 20: 1217 [DOI] [PubMed]
  • 21.Da Costa A, Lelièvre H, Pha D, Kirkorian G, Célard M, Chevalier P, Vandenesch F, Etienne J, Touboul P. Role of the preaxillary flora in pacemaker infections. Circulation. 1998;97:1791–1795. doi: 10.1161/01.CIR.97.18.1791. [DOI] [PubMed] [Google Scholar]
  • 22.Golzio PG, Fanelli AL, Vinci M, Pelissero E, Morello M, Marra WG, Gaita F. Lead vegetations in patients with local and systemic cardiac device infections: Prevalence, risk factors, and therapeutic effects. Europace. 2013;15:89–100. doi: 10.1093/europace/eus240. [DOI] [PubMed] [Google Scholar]
  • 23.Ipek EG, Guray U, Demirkan B, Guray Y, Aksu T. Infections of implantable cardiac rhythm devices: Predisposing factors and outcome. Acta Cardiol. 2012;67:303–310. doi: 10.1080/AC.67.3.2160719. [DOI] [PubMed] [Google Scholar]
  • 24.Polewczyk A, Jacheć W, Janion M, Podlaski R, Kutarski A. Lead-dependent infective endocarditis: The role of factors predisposing to its development in an analysis of 414 clinical cases. Pacing Clin. Electrophysiol. 2015;38:846–856. doi: 10.1111/pace.12615. [DOI] [PubMed] [Google Scholar]
  • 25.Madhavan M, Sohail MR, Friedman PA, Hayes DL, Steckelberg JM, Wilson WR, Baddour LM; Mayo Cardiovascular Infections Study Group. Outcomes in patients with cardiovascular implantable electronic devices and bacteremia caused by Gram-positive cocci other than Staphylococcus aureus. Circ Arrhythm Electrophysiol. 2010; 3: 639–645 [DOI] [PubMed]
  • 26.Falcone M, Tiseo G, Durante-Mangoni E, Ravasio V, Barbaro F, Ursi MP, Pasticci MB, Bassetti M, Grossi P, Venditti M, Rizzi M. Risk factors and outcomes of endocarditis due to non-HACEK gram-negative bacilli: Data from the prospective Multicenter Italian Endocarditis Study Cohort. Antimicrob Agents Chemother. 2018;27(62):e02208–2217. doi: 10.1128/AAC.02208-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Wang R, Li X, Wang Q, Zhang Y, Wang H. Microbiological characteristics and clinical features of cardiac implantable electronic device infections at a tertiary hospital in China. Front Microbiol. 2017;6(8):360. doi: 10.3389/fmicb.2017.00360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Viola GM, Awan LL, Darouiche RO. Nonstaphylococcal infections of cardiac implantable electronic devices. Circulation. 2010;18(121):2085–2091. doi: 10.1161/CIRCULATIONAHA.110.936708. [DOI] [PubMed] [Google Scholar]
  • 29.Esquer Garrigos Z, George MP, Vijayvargiya P, Tan EM, Farid S, Abu Saleh OM, Friedman PA, Steckelberg JM, DeSimone DC, Wilson WR, Baddour LM, Sohail MR. Clinical presentation, management, and outcomes of cardiovascular implantable electronic device infections due to Gram-negative versus Gram-positive bacteria. Mayo Clin Proc. 2019;94:1268–1277. doi: 10.1016/j.mayocp.2018.11.029. [DOI] [PubMed] [Google Scholar]
  • 30.Aleong RG, Zipse MM, Tompkins C, Aftab M, Varosy P, Sauer W, Kao D. Analysis of outcomes in 8304 patients undergoing lead extraction for infection. J Am Heart Assoc. 2020; 7; 9: e011473 [DOI] [PMC free article] [PubMed]
  • 31.Lee DH, Gracely EJ, Aleem SY, Kutalek SP, Vielemeyer O. Differences of mortality rates between pocket and nonpocket cardiovascular implantable electronic device infections. Pacing Clin Electrophysiol. 2015;38:1456–1463. doi: 10.1111/pace.12748. [DOI] [PubMed] [Google Scholar]
  • 32.Sohail MR, Henrikson CA, Braid-Forbes MJ, Forbes KF, Lerner DJ. Increased long-term mortality in patients with cardiovascular implantable electronic device infections. Pacing Clin Electrophysiol. 2015;38:231–239. doi: 10.1111/pace.12518. [DOI] [PubMed] [Google Scholar]
  • 33.Le KY, Sohail MR, Friedman PA, Uslan DZ, Cha SS, Hayes DL, Wilson WR, et al. Clinical predictors of cardiovascular implantable electronic device-related infective endocarditis. Pacing Clin Electrophysiol. 2011;34:450–459. doi: 10.1111/j.1540-8159.2010.02991.x. [DOI] [PubMed] [Google Scholar]
  • 34.Tarakji KG, Wazni OM, Harb S, Hsu A, Saliba W, Wilkoff BL. Risk factors for 1-year mortality among patients with cardiac implantable electronic device infection undergoing transvenous lead extraction: The impact of the infection type and the presence of vegetation on survival. Europace. 2014;16:1490–1495. doi: 10.1093/europace/euu147. [DOI] [PubMed] [Google Scholar]
  • 35.Nishii N, Morimoto Y, Miyoshi A, Tsukuda S, Miyamoto M, Kawada S, Nakagawa K, Watanabe A, Nakamura K, Morita H, Morimatsu H, Kusano N, Kasahara S, Shoda M, Ito H. Prognosis after lead extraction in patients with cardiac implantable electronic devices infection: Comparison of lead-related infective endocarditis with pocket infection in a Japanese single-center experience. J Arrhythm. 2019;28(35):654–663. doi: 10.1002/joa3.12164. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Maytin M, Jones SO, Epstein LM. Long-term mortality after transvenous lead extraction. Circ Arrhythm Electrophysiol. 2012;5:252–257. doi: 10.1161/CIRCEP.111.965277. [DOI] [PubMed] [Google Scholar]
  • 37.Habib A, Le KY, Baddour LM, Friedman PA, Hayes DL, Lohse CM, Wilson WR, Steckelberg JM, Sohail MR, Mayo Cardiovascular Infections Study Group Predictors of mortality in patients with cardiovascular implantable electronic device infections. Am J Cardiol. 2013;111:874–879. doi: 10.1016/j.amjcard.2012.11.052. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Tables. (52KB, docx)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES